Skip to main content

News Releases & Statements

News Releases & Statements

FDA Approves New Treatment Option for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Rye Brook, NY, August 10, 2021 - The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma  after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.

Read More

FDA Approves New Treatment Option For Chronic Graft-Versus-Host-Disease In Patients Ages 12 Years And Older

Rye Brook, N.Y., August 3, 2021 - The U.S. Food and Drug Administration (FDA) recently approved belumosudil (Rezurock™) in patients 12 years or older for the treatment chronic graft-versus-host-disease (GvHD) that has not responded or has stopped responding to earlier treatments.

Read More

FDA Approval: New Treatment Indication for Multiple Myeloma Drug

Rye Brook, N.Y., August 3, 2021 - The U.S. Read More

LLS Urges Blood Cancer Patients to get Vaccinated as its National Patient Registry Enters Next Phase in COVID-19 Vaccine Studies

Rye Brook, N.Y., July 15, 2021—The Leukemia & Lymphoma Society® (LLS) began recruitment this week for a new study evaluating T-cell immune response to COVID-19 vaccine among people with a current or past diagnosis of blood cancer. This invitation-only follow-up study will include a sub-set of participants from a larger LLS study examining COVID-19 spike antibody response to vaccination. Read More

FDA Approves a Targeted Treatment for a Rare Form of Blood Cancer

Rye Brook, NY, June 23, 2021 - The U.S. Food and Drug Administration (FDA) last week approved avapritinib (Ayvakit®) for the treatment of advanced systemic mastocytosis (SM) in adults, including patients with aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia. Avapritinib is a targeted treatment that inhibits a mutation in the KIT gene, which drives about 95% of the cases of this rare type of blood cancer.

Read More

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.  An LLS representative will respond as soon as possible.